Biotech Values

[urche]

CAMH

I really don't intend to prolong this discussion or further my reputation as a curmudgeon. I can accept the conclusion that current evidence suggests TWA testing has "implications for risk stratification and health policy".

Where I think we can agree to disagree is that I don't see how the results published so far can be applied by an INDIVIDUAL patient and an INDIVIDUAL doctor. With non-ischemic cardiomyopathy and a negative test, I think we can say the results could be used to avoid unnecessary AICD insertion. Other than that, I don't think we can say the test has the specificity or sensitivity to answer the critical questions it is supposed to address.

My mind really is open, believe it or not.

Urche